What INVESTORS want and need from NRTI: I hear you and

New Post Public Reply Private Reply Replies (0) Message Board
crookedneck g&l #573
What INVESTORS want and need from NRTI:

I hear you and understand what you are saying. Yes there is definitely a trust issue and I guess that is why I am so excited about the gold standard approach that NRTI has taken. Think about it for second.

They will have the support and endorsements from 5 of the top MMJ experts who have studied and worked in the MMJ field for a long time and are highly respected by their peers - That will go along way to instill trust in NRTI's CBD products and in turn, impress investors.

They are in perfect position to be FIRST-TO-MARKET w/CBD in RETAIL STORES across the US. When that happens and is announced, this stock will go crazy! Why? Because for the very first time, investors will see a real MMJ company with actual CBD product on store shelves across the US, instead of the same old online sales that is filled with numerous unscrupulous companies with non-uniform products that lack in efficacy and safety, which were merely used to suck in early investors, but not any sustaining and meaningful revenue. When investors realize that NRTI is the real deal that walks the talk and leads by example rather than hyped up PR's, they will have the confidence to invest.

Now add to that NRTI's distribution network already in place, along with their existing business relationships they developed over the past few years, that will quickly get these CBD products distributed throughout the US and on store shelves in a brand new explosive category. This exclusivity at the retail markets will have a huge impact on early sales, further bolstering confidence for investors.

One thing I forgot to mention is their manufacturing, which is second to none and certified to produce Best-In-Class Quality products that will be uniform in the highest quality ingredients for each and every bottle produced. That type of quality control will not only ensure completely safe products, but also highly efficacious products that will perform as labeled with an iron clad guarantee for the consumer. Investors will quickly come to understand that NRTI is also about HIGH QUALITY PRODUCTS that meet or exceed the industry standards.

Yes, this approach of theirs will go a long way in providing the type of confidence investors want and need to see before jumping back into the medical marijuana field. At the upcoming launch next week, some investors will feel confident enough to jump in early to get in on the ground floor, while others will wait until they have proven themselves in the CBD market. Of course by the time they have proven themselves in the market, the share price will have risen much higher than it will be at the launch time, but for some, this is what they will require and I can't blame them after the huge fall last year that caused many to lose substantial amounts of money in the MMJ market.

Next week is when it all kicks off and though we can't control the manipulative MM's with their unscrupulous shorting techniques, we can remain focused on the facts that surround NRTI and the fast growing CBD market that will be the fastest growing sector for the next 5 years. I sure don't want to miss this opportunity and I think there are plenty of others out there waiting for the right opportunity to invest in a real company they can trust in and NRTI will do just that! Cheers!

Inergetics Inc. (NRTI) Stock Research Links

NRTI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 0

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 0

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Conformal Coatings Market Set for Significant Growth by 2032

Updated Category News Views 233

The conformal coatings market surged ahead with projections showing it could reach USD 1.7 billion by 2032. This translates into a compound annual growth rate (CAGR) of 5.7% from 2024 to 2032, driven primarily by advancements in electronic protection technologies. Traders had better keep their eyes peeled—this ain't just a bump; it's a substantial shift. What’s...

Continue Reading
Japanese Mobile Battery Industry Forecasts Significant Growth

Updated Category News Views 122

Japan Mobile Battery Market Overview The mobile battery market in Japan is witnessing significant growth, with a valuation of JPY 207.96 billion in 2024 and projected to escalate to JPY 358.97 billion by 2033, marking a compound annual growth rate (CAGR) of 6.48% from 2025 to 2033. This growth trajectory highlights not only increasing consumer demands but also rapidly...

Continue Reading
Givastomig: A Promising Player in Gastric Cancer Therapy

Updated Category News Views 74

Givastomig's Advances in Gastric Cancer Research I-Mab (NASDAQ: IMAB), a biotech firm focused on developing cancer immunotherapies, recently presented exciting results from its Phase 1 clinical trial involving givastomig. This innovative bispecific antibody immunostimulant was unveiled at a prominent medical conference, demonstrating its effectiveness in treating advanced...

Continue Reading
Rani Therapeutics Partners with Chugai for Drug Delivery Breakthrough

Updated Category News Views 245

Rani Therapeutics Engages with Chugai Pharmaceutical Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) recently announced a significant collaborative effort with Chugai Pharmaceutical Co., Ltd., resulting in an enthusiastic response from investors. This collaboration aims to utilize Rani's innovative RaniPill oral drug delivery system alongside Chugai's experimental...

Continue Reading
Revizto's Brand Revamp: A Bold Step Towards Future Growth

Updated Category News Views 142

Revizto Introduces a Fresh Brand Identity As project complexities continue to rise in the construction industry, Revizto is making important modifications to its public image. The renowned collaboration platform, specifically designed for the Architecture, Engineering, Construction, and Operations (AECO) sectors, recently unveiled its refreshed brand identity,...

Continue Reading